Arjun Nathan

Urology Registrar @NorthLonUrol | @NIHRresearch Doctoral Research Fellow PhD | Co-Chair @BURSTurology | Founder @NSTS_ed

[BURST Urology @BURSTurology]

🧐 DAY 1: Can the experts defend the seemingly indefensible?

🚨 Prepare to have your assumptions challenged - this might just change your practice!

15 June |📍John Anderson | 🕝16.30-17.30

#BURSTatBAUS26 #UroSoMe

[BURST Urology @BURSTurology]

#BURSTatBAUS 2026 is on! 👇 

💭 Mon 15/6 16:30, John Anderson: Change My Mind! Evidence vs Experience

💡 Tue 16/6 14:15, Olympia: @TUF_tweets x BURST The Research X Factor

🤖 Wed 17/6 11:30 Paddy O’Reilly: Is the AI bubble about to BURST? 

See you in London! 🏙️

#UroSoMe

[BURST Urology @BURSTurology]

1/5 📢 𝗣𝗨𝗕𝗟𝗜𝗖𝗔𝗧𝗜𝗢𝗡 𝗔𝗟𝗘𝗥𝗧!

𝘞𝘩𝘢𝘵 𝘪𝘴 𝘵𝘩𝘦 𝘤𝘳𝘪𝘴𝘪𝘴? 🤔

1 in 5 acute surgical referrals in the UK are urological 🏥

Yet, 1 in 3 UK doctors lack confidence in assessing these admissions. We are seeing a major disconnect between clinical demand and frontline expertise.

#UroSoMe #MedEd

[Alexander Ng @AlexBCDNg]

⭐ Thrilled to see @COMPASSurology research cited in the #EAU26 PCa Guidelines!

📍 GLIMPSE (@radiology_rsna): Highlighting the global variation and feasibility of quality improvement

📍 PRIME (@JAMA_current): Confirming non-inferiority of bpMRI to mpMRI for csPCa detection

[BURST Urology @BURSTurology]

📣 𝐍𝐄𝐖𝐒 𝐅𝐋𝐀𝐒𝐇 - #WASHOUT 𝐇𝐀𝐒 𝐆𝐎𝐍𝐄 𝐕𝐈𝐑𝐀𝐋

🌍 We are incredibly proud and grateful that our latest flagship study has been featured by media outlets across the globe!

🔍 𝐊𝐞𝐲 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬:
🩸 ~25% of patients presenting with emergency haematuria had an underlying cancer

🚨 Mortality rate of almost 10%

🩻 Patients who did not receive investigations or appropriate treatment were 2.5× more likely to die within three months.

⏱️ Investigation within 48h reduced length of stay, readmissions and mortality

⌛️ No investigations or treatment in the first 48 hours increases length of stay by 5.6 days, mortality by 2.6% and readmission risk by 3.6%

🔑 𝐓𝐡𝐞 𝐦𝐞𝐬𝐬𝐚𝐠𝐞 𝐢𝐬 𝐜𝐥𝐞𝐚𝐫:
Visible haematuria should not be ignored. Rapid investigation is key for patients presenting with emergency haematuria with high rates of underlying malignancy.

📰 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬:
🇬🇧 The Sun
https://t.co/HGPtKSKZcR
🇬🇧 The Telegraph
https://t.co/vREZuZEZ0R
🇮🇪 Irish Independent
https://t.co/ZlHNVCB12X
🇪🇸 La Razón
https://t.co/qLwRTuUg1b
🇪🇸 El Debate
https://t.co/6c0HQTSc62
🇪🇸 El Diario
https://t.co/oM3gbJ3Mbs
🇬🇧🇦🇺 News Medical
https://t.co/6INyo0RjxK

🎥 Watch the full European Association of Urology TV interview with Co-Chief Investigator @NikitaB0709 - https://t.co/P5fWaDmNTw

👀 Full results coming very soon - watch this space!

A huge thank you to our collaborators behind #WASHOUT. We're also grateful to our funders for their support: @TUF_tweets Charles Reynolds Foundation @Actionbladderca and @RosetreesT

@NikitaB0709 @kgbyrnes @QuentinMak @BingjieChow @NikkiKerdegari @ippoliti_simona @AlexBCDNg @AquaAsif @ArjunSNathan @benchallacombe @veerukasi

[BURST Urology @BURSTurology]

🔥 𝐇𝐨𝐭 𝐨𝐟𝐟 𝐭𝐡𝐞 𝐩𝐫𝐞𝐬𝐬 -#WASHOUT featured in @Telegraph

🩸WASHOUT is the largest study to date investigating the management of emergency haematuria with 8,500+ patients across >350 hospitals globally

🔍 𝐖𝐡𝐚𝐭 𝐰𝐞 𝐟𝐨𝐮𝐧𝐝:

🩻 Patients who did not receive investigations or appropriate treatment were 2.5× more likely to die within three months.

🧬 Approximately one quarter of patients were found to have an underlying cancer.

⏰ For patients with underlying cancer, those having investigations within 48 hours received a diagnosis within one day on average, compared with ~3 weeks for those discharged without investigation.

🏥 Lack of investigation is associated with longer hospital stays.

❓𝐖𝐡𝐲 𝐭𝐡𝐢𝐬 𝐦𝐚𝐭𝐭𝐞𝐫𝐬:
Emergency haematuria is a prevalent urological emergency accounting for at least 15% of all urological emergency admissions in the UK and 10% readmitted within 30 days. Despite this, there are no standardised guidelines for management. 

🔑 Prompt investigation is crucial for timely diagnosis and treatment.

𝐅𝐢𝐧𝐝 𝐨𝐮𝐭 𝐦𝐨𝐫𝐞:
🔗 Check out the full article: https://t.co/vREZuZEZ0R

🎥 Watch the full interview, featuring our Co-Chief Investigator, @NikitaB0709, on @Uroweb EAU TV https://t.co/P5fWaDmNTw

👀 Full results will be out very soon - watch this space!

Thank you for all our sites and collaborators!

Thank you to our founders @TUF_tweets & Charles Reynolds Foundation, @Actionbladderca, and @RosetreesT

@NikitaB0709 @kgbyrnes @kmj_gallagher @QuentinMak @BingjieChow @NikkiKerdegari @ippoliti_simona @AlexBCDNg @AquaAsif @ArjunSNathan @benchallacombe @veerukasi

📄 https://t.co/IOpuVJ7XQI

[BURST Urology @BURSTurology]

1/ 📢 PUBLICATION ALERT!

#RESECT is one of @BURSTurology’s most ambitious studies, with a novel #trial design - a cluster RCT with 200+ sites with 15000+ patients, now in @EUplatinum ⚡

Can private, personal feedback and education about endoscopic surgery (TURBT) change surgeon behaviour and improve outcomes in bladder cancer? 🤔

Read HERE: https://t.co/OJzewK7g1l

[BURST Urology @BURSTurology]

BURST at #EAU26 | The Future of International Research

📅 Sat 14 Mar | 🕐 13:00-15:00 | 📍 Connaught 1

✅ #WASHOUT results & next steps
🌍 Global collaborator perspectives on international research
🚀 Open discussion: how to get involved with BURST

See you in London! #UroSoMe

[BURST Urology @BURSTurology]

We are proud to announce that BURST and @ManchesterAndro are bringing UK experts together to reach #consensus for the investigation, management and follow-up of priapism. Let's bring #CLARITY

[BURST Urology @BURSTurology]

📢 TUF x BURST: X-Factor is back for #BAUS26!

Got an idea (no prior research experience needed) & think it could change practice?

🏆 2 prizes (Overall Winner + People’s Choice)
💰 Share of £1000 🤑

⏰ NEW Deadline: 23:59, 12 Feb

#UroSoMe

Submit HERE: https://t.co/b5rCWkuqnl

[BURST Urology @BURSTurology]

Hear from PPI Partner, Derek Shep on the #ELIPSE Trial and why clear, patient-led information is important in prostate cancer research. 🔬

[BURST Urology @BURSTurology]

🔥TUF X BURST: X-Factor returns for #BAUS26 - this time bigger and better!

Got a QIP, audit or innovation idea? Submit it for a chance to have it refined, present at BAUS 26 and a shot at a share of £1,000!

⌛Deadline: 1st Feb 2026

🔗Link: https://t.co/b5rCWkuqnl

#UROSoMe

[BURST Urology @BURSTurology]

Excited to announce that we have partnered with the #PARTIAL team to help answer the question of partial vs radical #nephrectomy for localised #RCC 🔍

#UroSoMe

[BURST Urology @BURSTurology]

📢 Meet some of our new ELIPSE–BURST Associate PIs!

Interested in joining the network? 👩‍⚕️👨‍⚕️

Contact @BURSTUrology to find out more!

[BURST Urology @BURSTurology]

🤔 Got a question about the use of systemic anti-cancer treatment in metastatic prostate cancer? The @NPCA_uk is here to help!

Submit your questions and our expert panel will answer them in our webinar on 23 Oct 9am👉 https://t.co/gACnN369lD 

🔗 https://t.co/CfMFpELgMY

[BURST Urology @BURSTurology]

👇The programme for our webinar with @NPCA_uk on the use of systemic anti-cancer treatment in metastatic prostate cancer on 23 Oct 9am

🧬Evidence for use of ARPIs
💊Safe prescribing
🫀CV and bone health- mitigating effects of ADT ±ARPIs
🔎Case studies 

🔗https://t.co/sU7JhrQSKF

[BURST Urology @BURSTurology]

🚀 We are delighted to announce our upcoming webinar with @NPCA_uk - “The use of systemic anti-cancer treatment in metastatic prostate cancer.” 

🗓️ Join us on 23rd Oct for an evidence-based update on systemic therapy in metastatic prostate cancer

🔗 https://t.co/CfMFpELgMY

[Arjun Nathan @ArjunSNathan]

🆕 Great to see #PRIME published - an effective and efficient trial to determine a new standard of practice

👏 What you won’t see published is the amount of hard work carried out behind the scenes to deliver this work @veerukasi @AlexBCDNg @AquaAsif

Read 👇

[COMPASS Research Group · UCL 🧭 @COMPASSurology]

1/n 🔥HOT OFF THE PRESS🔥
#PRIME Trial just published @JAMA_current

⭐Level 1 evidence that biparametric MRI (- contrast) is non-inferior to multiparametric #MRI (+ contrast) for #prostatecancer detection

⏱️ for a new standard of care

🔗https://t.co/2E6pBrCf1y

#UroSoMe

[BURST Urology @BURSTurology]

❗Exciting news from @BURSTurology!

🤝 We’re proud to announce our partnership with the ELIPSE clinical trial team

🥇 This collaboration is a first for BURST, and embodies BURST’s mission of empowering the next generation of urologists.

[BURST Urology @BURSTurology]

Recruitment milestones so far:

✅ 300+ sites worldwide
✅ 8,500+ patients entered

🗓️ Final 3-month follow-up deadline:
Dec 2025

📝 Main paper expected late 2026

✨ A huge thank you to every collaborator driving #WASHOUT forward.

#UroSoMe #Haematuria